Better Health for All

The company's sole product, VYKAT XR, is the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome (PWS), a rare and life-threatening genetic disorder.

This addresses a substantial unmet medical need, with clinical data showing statistically significant improvement in hyperphagia (p=0.0022) and aiming to improve metabolic health, behavior, and cognitive symptoms. The drug is indicated for adults and children aged four years and older with PWS, a condition affecting an estimated 1 in 15,000 live births in the U.S. and 300,000-400,000 individuals worldwide. The company acknowledges a temporary disruption from a short-seller report and has identified a material weakness in its internal control over financial reporting related to information technology general controls. Soleno plans to invest up to $5 million in grant funding over the next year to support innovative genetic research for a potential PWS cure. The company launched Soleno OneTM, a patient support program, and is actively educating physicians and families, leveraging patient and community educators, and hosting community events. VYKAT XR has U.S. market exclusivity via Orphan Drug Designation for 7 years and potential 10-year exclusivity in the EU, establishing a rare orphan drug monopoly. Clinical trials adhere to good clinical practices, requiring informed consent and IRB/IEC approval, and patient data from a registry platform played a pivotal role in FDA approval. The company's Code of Business Conduct and Ethics emphasizes maintaining confidentiality of information and complying with privacy laws like HIPAA.

Fair Money & Economic Opportunity

Soleno Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases.

As such, it does not offer lending, deposit, or other consumer financial services. Therefore, KPIs related to APRs, fees, loan books, debt burden, and open banking APIs are not applicable to its core business model. The company's product, VYKAT XR, is a once-daily oral treatment for Prader-Willi Syndrome. While the annual cost of the drug is approximately $466,000, Soleno offers patient support programs (Soleno One) that include financial support options, copay assistance that may reduce out-of-pocket costs to $0 for eligible patients, and no-cost prescriptions for uninsured or underinsured patients. These programs also provide personalized education and resources for navigating treatment and the insurance process, which is medical/access literacy, not financial literacy. The company does not generate or manage customer financial data, nor does it have a loan or insurance book.

Fair Pay & Worker Respect

No specific quantitative data was found in the provided articles to assess Soleno Therapeutics, Inc. against any of the Fair Pay & Worker Respect KPIs. While executive compensation details were provided, median employee compensation for the entire workforce was not, preventing the calculation of the CEO median pay ratio.

A qualitative mention of "minimal coverage" for health insurance was noted, but no specific percentage was provided to map to the rubric's tiers. Similarly, an employee rating of -0.1/5 stars for compensation and benefits was mentioned, but this is not a direct measure of the worker engagement score as defined by the rubric, which requires an index on a 0-100 scale.

Fair Trade & Ethical Sourcing

No specific, quantitative evidence was found across the provided articles to assess Soleno Therapeutics, Inc. against the Fair Trade & Ethical Sourcing value.

Information regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend was not available.

Honest & Fair Business

Soleno Therapeutics, Inc. has a Whistleblower Policy that allows employees to report concerns about accounting, fraud, SEC violations, and Code of Ethics breaches.

It provides multiple reporting channels, including a 24/7 confidential independent secure web portal and a reporting hotline. The policy explicitly prohibits retaliation against employees who report in good faith, and complaints related to accounting and auditing are logged and reported quarterly to the Audit Committee. The company has a "zero tolerance" anti-corruption policy that strictly prohibits all forms of bribery and corruption, and it represents compliance with anti-corruption laws such as the FCPA and UK Bribery Act. The company has had zero financial restatements in the past five years.

Planet-Friendly Business

No specific, quantitative data points were found in the provided articles to assess Soleno Therapeutics, Inc. against any of the 'Planet-Friendly Business' KPIs. The articles mention proprietary ESG scores such as 'Negative GHG Emissions Score', 'Negative Biodiversity Score', and 'Negative Waste Score', but these are not the underlying metrics (e.g., tCO₂e, percentage of land conserved, waste diversion rate) required by the rubric's quantitative thresholds.

Therefore, all KPIs are omitted due to lack of evidence.

Safe & Smart Tech

The company provides users with rights to access, object to processing, delete, opt-out of sale, rectify, transmit, and withdraw consent for their personal information, with requests completed within thirty days.

However, the company identified a material weakness in internal controls related to ineffective design and operation of certain information technology general controls (ITGCs), including segregation of incompatible duties, program change management, and user access controls. The company states it implements technical safeguards like firewalls, intrusion prevention, anti-malware, and access controls, which are evaluated and improved through vulnerability assessments, cybersecurity threat intelligence, and outside audits and certifications.

Zero Waste & Sustainable Products

No specific, concrete data points or initiatives related to waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction, hazardous waste management, product durability, repairability, waste audits, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education were found in the provided articles for Soleno Therapeutics, Inc.

The articles primarily focus on financial reporting, clinical trials, regulatory approvals, and general ESG risk ratings without specific sustainability metrics.